Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI

Core Viewpoint - Evercore ISI has raised the price target for Crispr Therapeutics (CRSP) to $74 from $62, maintaining an Outperform rating, indicating strong momentum in the company's prospects [1]. Group 1: Price Target and Rating - The price target for Crispr Therapeutics has been increased to $74, reflecting a positive outlook [1]. - The previous price target was $62, showing a significant upward revision [1]. - The Outperform rating suggests that analysts expect the stock to perform better than the market average [1]. Group 2: Market Context - Vertex Pharmaceuticals' new guidance for Casgevy is described as "promising," contributing to the positive sentiment around Crispr Therapeutics [1]. - The analyst believes that the setup for Crispr appears even better than initially appreciated, indicating potential for further growth [1].